Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
Spyre Therapeutics, Inc. officer Scott Burrows reported a proposed sale of 17,500 common shares, with an aggregate market value of $1,573,157.25, scheduled for September 30, 2026. The notice identifies Morgan Stanley Smith Barney LLC Executive Financial Services as broker and Nasdaq as the exchange. It also lists a cash stock-option exercise from the issuer for 17,500 common shares on September 30, 2026.
Spyre Therapeutics, Inc. (SYRE) reported positive Part A induction topline data from its Phase 2 SKYLINE trial of SPY003, an anti-IL-23 antibody for moderately-to-severely active ulcerative colitis. SPY003 met the primary endpoint with a 10.0‑point reduction in Robarts Histopathology Index (RHI) at Week 12 (p<0.0001), alongside clinical remission and endoscopic improvement rates the company highlights as in line with the IL‑23 class.
The 10.0‑point RHI reduction was similar to previously reported reductions of 9.2 for SPY001 and 10.7 for SPY002, and the company states these are among the largest improvements seen in ulcerative colitis studies. In 44 SPY003 patients, 43% experienced treatment‑emergent adverse events, with 11% severe adverse events, 1 drug‑related adverse event, no drug‑related serious adverse events, and no deaths. Part B of SKYLINE, testing pairwise combinations of SPY001, SPY002 and SPY003, is enrolling, with topline induction data expected in 2027 and additional readouts from other IBD and immunology programs expected between late 2026 and early 2028.
Spyre Therapeutics, Inc. (SYRE) officer Heidy King-Jones reported exercising stock options for 28,399 shares of common stock at an exercise price of $14.50 per share on September 1–2, 2026, and selling 28,399 shares of common stock in multiple transactions at prices up to $90.00 per share.
The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026, with several sales reported at weighted-average prices reflecting trade ranges between $85.71 and $88.69 per share.
Spyre Therapeutics, Inc. (SYRE) reported that Chief Financial Officer Scott L. Burrows exercised stock options for 7,500 shares of common stock on September 1, 2026 at an exercise price of $14.50 per share, then sold portions of the resulting shares in multiple open-market transactions that day at weighted-average prices between $86.25 and $89.04, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. On September 2, 2026 he also sold 18,232 shares at $89.35 per share to satisfy tax withholding obligations in connection with the settlement of 33,738 restricted stock units, described as a sell-to-cover transaction rather than a discretionary trade. Following the option exercise, he continued to hold options covering 337,357 shares of common stock expiring on September 1, 2033.
Spyre Therapeutics, Inc. (SYRE) reports that Chief Executive Officer and director Turtle Cameron sold 15,000 shares of common stock on September 1, 2026 in four open-market transactions at weighted average prices of $86.36, $87.15, $88.06, and $89.07.
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025, with each price reflecting multiple trades within stated ranges. A footnote also states that Cameron has 43,593 shares scheduled to vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics, Inc. (SYRE) received a Rule 144 notice indicating that officer Heidy King-Jones plans to sell up to 46,665 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with sales planned beginning on or about 09/01/2026.
The shares were and will be acquired upon the exercise of stock options over the next three months, with the dates of acquisition and payment matching the exercise/sale dates. The filing lists an aggregate market value of approximately $4,168,584.45 for the shares and notes 88,173,762 shares outstanding as of 09/01/2026.
Spyre Therapeutics, Inc. (SYRE) reported topline data from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. In patients with moderate to severely active RA, SPY072 Low Dose achieved a statistically significant improvement in the primary endpoint, change from baseline in DAS28-CRP at Week 12 versus placebo. High and Low Dose arms also showed nominally significant advantages on key secondary and exploratory endpoints, including ACR20 and ACR50 response rates. SPY072 was well tolerated, with overall adverse event rates similar to placebo and no drug-related serious adverse events. The company stated that while the magnitude of effect did not meet its internal threshold to prioritize SPY072 as a monotherapy in RA, the data provide proof-of-mechanism for TL1A and support its potential in other autoimmune diseases and as a combination component. Spyre highlighted upcoming topline readouts across its I&I pipeline through 2027, including SPY003 in ulcerative colitis, additional SPY072 sub-studies in psoriatic arthritis and axial spondyloarthritis, and a combination study of SPY072 with IL-17A/F in hidradenitis suppurativa.
Spyre Therapeutics, Inc. has an institutional holder group led by Perceptive Advisors LLC reporting beneficial ownership of 4,319,496 shares of common stock. This represents 4.9% of the outstanding shares, based on 88,173,762 shares of common stock outstanding as of July 28, 2026.
The shares are held directly by Perceptive Life Sciences Master Fund, Ltd., while Perceptive Advisors LLC, as investment manager, and Joseph Edelman, as managing member of Perceptive Advisors, may be deemed to share voting and dispositive power over these shares. Each reporting person reports shared voting and dispositive power over 4,319,496 shares and no sole voting or dispositive power, and confirms ownership of 5 percent or less of this class.
Spyre Therapeutics, Inc. received an updated Schedule 13G/A (Amendment No. 2) reporting ownership by RTW Investments, LP and its managing partner and CIO, Roderick Wong, M.D. The reporting persons collectively report beneficial ownership of 4,251,996 shares of common stock, representing 4.8% of the class.
The shares are held by certain RTW-managed funds, with RTW Investments and Dr. Wong reporting shared voting and dispositive power over all 4,251,996 shares and no sole voting or dispositive power. The ownership percentage is based on 87,936,477 shares outstanding as of June 24, 2026 as reported by the company.
Spyre Therapeutics, Inc. director Jeffrey W. Albers reported an option exercise and related share sales on August 7, 2026. He exercised stock options covering 5,000 shares of common stock at a $10.39 exercise price and retained options on 45,000 shares. On the same date, he reported sales totaling 23,000 shares of common stock at weighted average prices slightly above $104 per share, including sales by Sessions LLC reported as indirect ownership. All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.